US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.34

-0.7701-1.79%

Post-market: 42.340.00000.00%16:10 EDT

Volume:2K

Turnover:64.58K

Market Cap:31.75M

PE:- -

High:42.35

Open:42.35

Low:42.34

Close:43.11

52wk High:43.11

52wk Low:29.32

Shares:750.00K

Float Shares:750.00K

Volume Ratio:2.57

T/O Rate:0.20%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

China's Green Fuel Sector Shifts from Pilot Projects to Mass Production

Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares

Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing

Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

RBC Capital Remains a Buy on GH Research (GHRS)

Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 2,000 Common Shares Worth $641,800

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)

Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook

Benzinga Earnings

Natera up over 19%, on Pace for Record High Close

Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?

Simply Wall St.

Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline

Natera, Inc. : Canaccord Genuity Raises Target Price to $375 from $330

THOMSON REUTERS

Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)

Natera, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Natera Q2 FY26 Net Loss Narrows 33.65% to $67 Million; Revenue Rises 37.7% to $752.8 Million

Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/HELX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.3399,"timestamp":1787601600000,"preClose":43.11,"halted":0,"volume":1524,"hourTrading":{"tag":"盘后","latestPrice":42.3399,"preClose":42.3399,"latestTime":"16:10 EDT","volume":10,"amount":423.399,"timestamp":1787602205265,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01786360473208071,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":-0.7701,"latestTime":"08-24 18:18:20 EDT","open":42.35,"high":42.35,"low":42.3399,"amount":64576,"amplitude":0.000234,"askPrice":63.76,"askSize":200,"bidPrice":21.26,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":43.11,"sharesOutstanding":650000,"nav":43.201,"aum":32400497.63,"dividendRate":0.003361,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.3399,"preClose":42.3399,"latestTime":"16:10 EDT","volume":10,"amount":423.399,"timestamp":1787602205265,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.565656,"impliedVol":0.2459,"impliedVolPercentile":0.8606},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.565656,"shares":750000,"dividePrice":0.1423,"high":42.35,"amplitude":0.000234,"preClose":43.11,"low":42.3399,"week52Low":29.32,"pbRate":"--","week52High":43.11,"institutionHeld":0,"latestPrice":42.3399,"eps":0,"divideRate":0.003361,"volume":1524,"delay":0,"ttmEps":0,"open":42.35,"prevYearClose":36.3062,"prevWeekClose":43.11,"prevMonthClose":38.8312,"prevQuarterClose":39.9651,"fiveDayClose":41.1366,"twentyDayClose":38.8569,"sixtyDayClose":34.2035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1109741990","title":"China's Green Fuel Sector Shifts from Pilot Projects to Mass Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1109741990","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109741990?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:20","pubTimestamp":1786504847,"startTime":"0","endTime":"0","summary":" As global climate governance enters a critical phase, green fuel, a key link between renewable energy and end-use consumption, is transitioning from an \"option\" to a \"necessity.\" Li Zhongwu,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949165","title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949165","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:23","pubTimestamp":1786487005,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Commercial Officer Chris Freeman disposes of $ 10.75 million in common sharesGuardant Health Chief Commercial Officer Chris Freeman exercised stock options for 63,605 shares on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4khYKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GDOC","LU0109394709.USD","BK4585","EKG","FFOX","PTH","GNMX","GNOM","HELX","BK4551","LU0889565916.HKD","BK4535","LU0320765992.SGD","BK4588","GH","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658737957","title":"Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658737957","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658737957?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:36","pubTimestamp":1786401393,"startTime":"0","endTime":"0","summary":"An announcement from Qiagen ( ($QGEN) ) is now available. Qiagen N.V., a Netherlands-based life sciences and molecular diagnostics company headquar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/goldman-sachs-discloses-2-63-voting-interest-in-qiagen-via-afm-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/goldman-sachs-discloses-2-63-voting-interest-in-qiagen-via-afm-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034235188.USD","LU1791807156.HKD","LU0345770308.USD","LU2237443465.HKD","HELX","LU1894683348.USD","LU0345770993.USD","LU1804176565.USD","LU2237443895.HKD","LU1868837300.USD","BK4127","IE00BFXG1179.USD","BK4516","LU2471134796.USD","IE00B19Z3581.USD","LU2237443382.USD","BK4552","GSX","LU0251131958.USD","IE0004086264.USD","LU0048573561.USD","LU1868837136.USD","HTEC","LU2265009873.SGD","LU2471134952.CNY","IE00BSNM7G36.USD","LU1868836591.USD","BK4585","LU1668664300.SGD","BK4550","BK4504","LU0061475181.USD","BK4588","LU2750360641.GBP","BK4533","BMED","GS","LU2471134879.HKD","LU0942090050.USD","LU1894683264.USD","IE0004091025.USD","LU2237438978.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0251142724.SGD","LU2237443978.SGD","GNMX","LU2237443622.USD","LU1868836757.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658599689","title":"Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2658599689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658599689?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:13","pubTimestamp":1786392812,"startTime":"0","endTime":"0","summary":"Guardant Health grants 46,044 RSUs to 149 new employees under inducement planGuardant Health set inducement RSU grants covering 46,044 common shares for 149 new non-executive hires, with an Aug. 3, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL208d3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GNOM","GDOC","BK4535","BK4551","LU0320765992.SGD","PTH","EKG","GH","BK4196","GNMX","LU0109394709.USD","BK4585","LU0889565916.HKD","HELX","FFOX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GH","LU0109394709.USD","BK4007","EKG","FFOX","BK4535","BK4551","PTH","LU0889565916.HKD","GNMX","LFSC","GDOC","GNOM","HELX","BK4539","PSIL","LU0320765992.SGD","BK4196","BK4585","GHRS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GSIB","LU0128525929.USD","PTH","BK4207","GNMX","GDOC","BK4551","LU0310800379.SGD","LU1267930573.SGD","PSIL","BK4535","LU0889565916.HKD","GHRS","EKG","LU0708994859.HKD","GH","LU0029864427.USD","GNOM","HELX","LU0109394709.USD","BK4196","LFSC","LU0320765992.SGD","BK4007","BK4539","FFOX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622568","title":"Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 2,000 Common Shares Worth $641,800","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622568","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657622568?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:35","pubTimestamp":1786152953,"startTime":"0","endTime":"0","summary":"Natera Executive Chairman Matthew Rabinowitz reports disposal of 2,000 common shares worth $641,800Natera Executive Chairman Matthew Rabinowitz reported a sale of 2,000 common shares on Aug. 7 at USD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260808:nNDLSJWxn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 2,000 Common Shares Worth $641,800","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2264538146.SGD","LU2324357040.USD","LU1064131342.USD","LU0345770993.USD","LU2065171402.SGD","LU0053671581.USD","GNOM","LU0012050646.USD","LU2065171311.SGD","HELX","LU1988902786.USD","LU0106261612.USD","LU0345770308.USD","LU2065731478.USD","BK4139","LU0963586101.USD","NTRA","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629107","title":"Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629107","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629107?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:12","pubTimestamp":1786137124,"startTime":"0","endTime":"0","summary":"Canada's DRI Healthcare Q2 income rises, helped by milestone events in royalty portfolioOverviewCanada pharmaceutical royalty investor's Q2 total income rose to a record $50.1 mlnAdjusted EBITDA margi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N444109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","IHE","LU1559883803.SGD","LGND","HELX","XNCR","RPRX","IE0009354923.USD","LU0566484027.USD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GH","GDOC","INMD","XLV","BK4581","XBI","SRRK","HELX","LABU","BK4082","EKG","GNOM","BK4137","THNR","PTH","LU0889565916.HKD","LU0029874061.USD","LFSC","BK4139","BK4007","BK4551","BK4535","LU0109394709.USD","HCSG","GNMX","PSIL","IBRN","LU0128526141.USD","BK4196","GHRS","LU0320765992.SGD","BK4539","BK4585","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663625","title":"Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663625?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:40","pubTimestamp":1786131636,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ligand Pharma (LGND), AMN Healthcare Services (AMN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-amn-healthcare-services-amn-and-warby-parker-wrby-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-amn-healthcare-services-amn-and-warby-parker-wrby-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XBI","WRBY","BK4200","BK4139","BK4007","LGND","LU1559883803.SGD","XLV","HELX","IE0009354923.USD","BK4196","BK4585","LU0566484027.USD","AMN","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657235366","title":"Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657235366","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657235366?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:35","pubTimestamp":1786127721,"startTime":"0","endTime":"0","summary":"Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/08/61052706/natera-ceo-says-company-is-clearly-on-a-roll-after-record-test-volumes-raises-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU1064131342.USD","LU0963586101.USD","HELX","LU1988902786.USD","LU2065170008.USD","LU0053671581.USD","BK4139","LU2324357040.USD","LU2065169927.USD","LU0345770993.USD","LU2065731478.USD","LU0106261612.USD","NTRA","LU2065171402.SGD","GNOM","LU2065171311.SGD","LU0012050646.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657362840","title":"Natera up over 19%, on Pace for Record High Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2657362840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657362840?lang=en_us&edition=fundamental","pubTime":"2026-08-08 01:53","pubTimestamp":1786125180,"startTime":"0","endTime":"0","summary":"Natera, Inc.  is currently at $317.76, up $52.39 or 19.74%--Would be new all-time closing high --On pace for largest percent increase since May 7, 2020, when it rose 21.37%--Snaps a two day losing streak--Up 18.68% this week; best weekly performance since the week ending March 1, 2024, when it rose 26.89%--Up 18.68% month-to-date--Up 38.71% year-to-date--Up 109.12% from 52 weeks ago , when it closed at $151.95--Would be a new 52-week closing high--Up 109.12% from its 52-week closing low of $151.95 on Aug. 8, 2025--Traded as high as $322.00; new all-time intraday high --Up 21.33% at today's intraday high; largest intraday percent increase since Nov. 13, 2024, when it rose as much as 24.18%All data as of 1:50:36 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","LU0345770308.USD","LU2065171402.SGD","LU2065170008.USD","LU1064131342.USD","LU2065731478.USD","LU2264538146.SGD","LU0106261612.USD","BK4139","LU2324357040.USD","LU0963586101.USD","LU2065169927.USD","LU0012050646.USD","LU1988902786.USD","GNOM","LU0345770993.USD","LU2065171311.SGD","LU0053671581.USD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619974","title":"Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619974","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619974?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:37","pubTimestamp":1786088256,"startTime":"0","endTime":"0","summary":"Why Ligand Pharmaceuticals Stock Is Back In Focus After Q2 Results\nLigand Pharmaceuticals (LGND) is back on investor radar after Q2 2026 earnings, a completed royalty acquisition, fresh zero coupon convertible financing, and updated full year guidance released on August 6.\nSee our latest analysis for Ligand Pharmaceuticals.\nThe share price reaction to Ligand Pharmaceuticals' Q2 announcement has been mixed, with a 1 day share price return of a 0.8% decline and a 30 day share price return down...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-posts-strong-q2-results-is-the-u","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-posts-strong-q2-results-is-the-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LGND","IE0009354923.USD","LU1559883803.SGD","HELX","BK4139","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369495","title":"Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657369495?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:11","pubTimestamp":1786083103,"startTime":"0","endTime":"0","summary":"An update from Oxford BioMedica ( ($GB:OXB) ) is now available. Oxford Biomedica, a specialist cell and gene therapy CDMO, reported around 9% reven...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","BK4588","CNCR","GNOM","SYNB","JDOC","OXM","IDNA","IBBQ","LFSC","WDNA","BK4585","IBB","TBXU","BK4202","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699263","title":"Natera, Inc. : Canaccord Genuity Raises Target Price to $375 from $330","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699263?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:36","pubTimestamp":1786081006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4440D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LU1064131342.USD","LU2065171402.SGD","LU0345770308.USD","LU2065731478.USD","LU0106261612.USD","LU0053671581.USD","LU0012050646.USD","LU2264538146.SGD","BK4139","LU0345770993.USD","LU2065171311.SGD","GNOM","LU1988902786.USD","LU0963586101.USD","NTRA","LU2324357040.USD","LU2065170008.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699655","title":"Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:20","pubTimestamp":1786080009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunocore Holdings (IMCR) and Natera (NTRA) with bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345770308.USD","LU2065171402.SGD","LU0053671581.USD","IMCR","GNOM","LU2065731478.USD","BK4505","LU0106261612.USD","LU2065171311.SGD","LU0963586101.USD","LU2264538146.SGD","LU2065169927.USD","HELX","LU1988902786.USD","LU0012050646.USD","LU1064131342.USD","LU2065170008.USD","BK4139","NTRA","LU2324357040.USD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663010","title":"Natera, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663010","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663010?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:02","pubTimestamp":1786050125,"startTime":"0","endTime":"0","summary":"Natera, Inc. reports results for the quarter ended June 30 - Earnings SummaryNatera, Inc.NTRA.OQreported a quarterly adjusted loss of 47 cents per share for the quarter ended June 30, higher than the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU2065171402.SGD","LU0053671581.USD","GNOM","LU2065731478.USD","LU0106261612.USD","LU2065171311.SGD","LU0963586101.USD","LU2264538146.SGD","LU2065169927.USD","HELX","LU1988902786.USD","LU0012050646.USD","LU1064131342.USD","LU2065170008.USD","BK4139","NTRA","LU2324357040.USD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657415668","title":"Natera Q2 FY26 Net Loss Narrows 33.65% to $67 Million; Revenue Rises 37.7% to $752.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657415668","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657415668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:35","pubTimestamp":1786048552,"startTime":"0","endTime":"0","summary":"Natera Q2 FY26 net loss narrows 33.65% to $67 million; revenue rises 37.7% to $752.8 millionNatera posted Q2 2026 revenue of USD 752.8 million, up 37.7% year over year.Net loss narrowed to USD 67 mill","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7Zqsnw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2264538146.SGD","LU2065171402.SGD","HELX","LU0345770993.USD","LU0053671581.USD","LU0963586101.USD","LU0106261612.USD","LU0345770308.USD","NTRA","LU1064131342.USD","LU1988902786.USD","BK4139","GNOM","LU2065169927.USD","LU2065170008.USD","LU2065731478.USD","LU0012050646.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650498","title":"Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650498","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650498?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:21","pubTimestamp":1786047704,"startTime":"0","endTime":"0","summary":"Natera Q2 revenue rises beats estimates on higher overall test volumes, raises 2026 outlookOverviewGenetic testing firm's Q2 revenue grew 38%, beating analyst expectationsCompany raised 2026 annual re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","BK4139","LU1064131342.USD","LU2324357040.USD","LU0053671581.USD","BK4104","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD","LU0963586101.USD","CAI","LU1988902786.USD","LU0106261612.USD","LU2065171402.SGD","LU0012050646.USD","GNOM","NTRA","LU2264538146.SGD","LU2065731478.USD","BK4121","LU0345770308.USD","PSNL","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657085","title":"Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657085?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047072,"startTime":"0","endTime":"0","summary":"Halozyme Q2 revenue jumps 48%, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany raised 2026 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","LU0053671581.USD","HELX","RPRX","LGND","LU1559883803.SGD","PBE","FFOX","BK4007","IE0009354923.USD","KYMR","LU0566484027.USD","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}